Psoriasis
Novel TYK2 inhibitor ICP-488 shows efficacy, safety in plaque psoriasis
ICP-488 demonstrated “excellent” efficacy and safety for the treatment of moderate to severe plaque psoriasis in adults, InnoCare Pharma announced in a press release.
Imuldosa snags FDA approval as fifth Stelara biosimilar in mounting market logjam
The FDA has approved the Stelara biosimilar, Imuldosa, for Crohn’s disease, ulcerative colitis and all other indications of the reference product, and the latest addition to the Stelara biosimilar bottleneck set to release in 2025.
Bimekizumab maintains scalp, palmoplantar psoriasis clearance through 4 years
Patients with scalp and palmoplantar psoriasis treated with bimekizumab had a high rate of clearance maintained through 4 years of treatment, according to a poster presented at the European Academy of Dermatology and Venereology Congress.
TYK-2 inhibitor effective over 7 months for treatment of plaque psoriasis
ESK-001 demonstrates continued efficacy for the treatment of moderate to severe plaque psoriasis over the span of 7 months, according to a late-breaker presentation at the European Academy of Dermatology and Venereology Congress.
Patients with psoriasis more likely to have obsessive-compulsive disorder
A new study further confirmed the association between obsessive-compulsive disorder and psoriasis, stressing the need for dermatologists to be vigilant.
Risankizumab shows real-world efficacy in psoriasis
Risankizumab showed a significant improvement in psoriasis severity and quality of life in biologic-naïve patients and in those previously treated with other biologics, according to a study.
Dual therapy can have ‘synergistic effect’ in difficult-to-treat inflammatory diseases
SAN DIEGO — Certain dual therapy strategies, including interleukin-17 plus IL-23 inhibition, or Janus kinase inhibitors alongside TNF inhibitors, can be effective for difficult-to-treat inflammatory diseases, according to a speaker here.
‘It’s going to be ubiquitous’: Weight loss drugs may aid rheumatic disease treatment
SAN DIEGO — GLP-1 agonists and other drugs that have recently made headlines for their weight loss applications will be useful in helping patients meet goals in psoriatic arthritis and other rheumatic diseases, according to a speaker here.
Phase 3, real-world data show deucravacitinib efficacious for scalp, overall psoriasis
Deucravacitinib proved to be efficacious in the treatment of moderate to severe scalp psoriasis and less extensive overall psoriasis, according to two presentations at the European Academy of Dermatology and Venerology Congress.
Healio Minute Podcast, Rheumatology/Psoriatic Arthritis Edition: Top Headlines - Week of September 23, 2024
In this edition, blue-collar workers more likely to miss work or quit due to psoriatic arthritis, infliximab biosimilar increase after release of a third option and more.